Evogene (NASDAQ:EVGN – Get Free Report) announced its earnings results on Wednesday. The biotechnology company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.33), FiscalAI reports. Evogene had a negative net margin of 214.57% and a negative return on equity of 121.44%. The company had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.35 million.
Evogene Stock Up 4.4%
Shares of NASDAQ EVGN opened at $0.73 on Wednesday. The company has a market cap of $6.37 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Evogene has a 12 month low of $0.70 and a 12 month high of $2.42. The business has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.96.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. Citadel Advisors LLC raised its position in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. Jane Street Group LLC raised its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,387 shares during the period. Finally, XTX Topco Ltd acquired a new position in Evogene during the fourth quarter valued at $25,000. 10.40% of the stock is owned by institutional investors and hedge funds.
Evogene Company Profile
Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.
In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.
Featured Articles
- Five stocks we like better than Evogene
- Palo Alto Networks Up 70%: Can the Rally Last Into June?
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
